Cardiovascular effects of troglitazone

Annals of Pharmacotherapy

Volumn 33, Issue 2, 1999, Pages 229-232

  Umland, Elena M ^a   Romanelli, Angela M ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Philadelphia College of Pharmacy Univ of the Sci in Philadelphia ^*

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ADVERSE DRUG REACTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033049621     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18028     Document Type: Article

References (18)

1. Vokonas PS, Kannel WB. Diabetes mellitus and coronary heart disease in the elderly. Clin Geriatr Med 1996;12:69-78.
2. SHEP Cooperative Research Group. Implications of the systolic hypertension in the elderly program. The systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-64.
3. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304-10.
4. Fernandez-Britto JE, Bacallao J, Castillo JA, Campos R, Wong R, Guski H. Atherosclerosis in diabetes and hypertension. A comparative morphometric study of their progression using an atherometric system. Zentralbl Pathol 1991;137:487-91.
5. National High Blood Pressure Education Program Working Group. National high blood pressure education program working group on hypertension in diabetes. Hypertension 1994;23:145-58.
6. Epstein M. Diabetes and hypertension: the bad companions. J Hypertension 1997;15(suppl 2):S55-S62.
7. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
8. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Maggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-9.
9. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9.
10. Sirom AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202.
11. Ogihara T, Rakugi H, Idegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
12. Nagasaka Y, Kaku K, Nakamura K, Kaneko T. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol 1995;50:1109-11.
13. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996;123:227-34.
14. Cominacini L, Garbin U, Pasini AF, Campagnola M, Davoli A, Foot E, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998;47:130-3.
15. Steinberg D, Parthasanathy SS, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:919-24.
16. Jellin J, ed. Patient testing and labeling strengthened for Rezulin. Pharm Lett 1998;13:70.
17. US Food and Drug Administration Safety Page. Available at: http:// www.fda.gov/medwatch/safety/1998/rezuli.htm. Accessed July 1998.
18. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin dependent diabetes mellitus (NIDDM): the NIDDM patient outcomes research team. Am J Med 1997;102:38-47.